ZEN-BIO, INC.
- DURHAM, NC 27713-1829
- zen-bio.com (company website, opens in a new tab)
- Corporate Entity (Not Tax Exempt)
- SAM active
- No verified credentials yet
- CMMCNot on file
- SPRSNone
- FCLVisible to paid members
- Small Business
Registration and small-business types: SAM.gov, synced Nov 9, 2026. Compliance: self-attested by the company unless marked verified. The SPRS chip shows a range, never the exact score. How verification works
- 36-mo obligations
- $0
- Awards on record
- 0
- Contract vehicles
- 0
- Verified credentials
- 0
Compliance posture: unverified (SAM.gov baseline only)
ZEN-BIO, INC. has not claimed this profile. What you see comes from public SAM.gov and USAspending records; no one from the company has confirmed CMMC, SPRS or clearance details yet. Learn more about CMMC 2.0
About ZEN-BIO, INC.
- Headquarters
- DURHAM, NC 27713-1829
Identifiers
UEI and CAGE come from SAM.gov. Other identifiers are listed by the company.
- UEILQS2WJFBBUQ3
- CAGE3MZW4
Capabilities & differentiators
No capability narrative yet
Compliance posture
No compliance posture published yet
Facility clearance
Facility clearance: visible to paid members
Clearance levels are shown only to paying members; TeamingIndex does not advertise clearances (NISPOM 32 CFR 117.9). Learn more about facility clearances · Compare plans
Past performance
No federal prime awards on record
Contract vehicles
No contract vehicles on file
Proven teaming graph
No sub-award reports yet
Source: USAspending.gov sub-award reports (FSRS) (opens in a new tab) · sync date not recorded · Prime contractors report first-tier subcontracts of $30,000 or more. Amounts are reported sub-award values.
SBIR/STTR portfolio
SBIR/STTR awardee — Phase III-eligible for work derived from its SBIR/STTR projects
Agencies may award follow-on Phase III work without a new competition when it builds on this company’s earlier SBIR/STTR projects. Other work is competed as usual.
- Awards on record
- 25 awards
- Total awarded
- $16,356,237
- By phase
- SBIR Phase I: 15
- SBIR Phase II: 8
- STTR Phase I: 2
- By agency
- Department of Health and Human Services: 25
- Active projects
- 0 projects
- Projects whose contract end date is today or later.
- Phase II ending within 12 months
- 0 projects
- Phase II projects ending within 12 months. Agencies may award Phase III work without a new competition only when it derives from, extends or completes these projects.
- By year
- 2019: 1
- 2018: 2
- 2017: 1
- 2016: 2
- 2015: 2
- 2014: 2
- 2013: 1
- 2012: 1
- 2011: 2
- 2010: 3
- 2009: 1
- 2008: 3
- 2007: 2
- 2005: 1
- 2003: 1
Awards (most recent first)
Tuned stem cell extracellular vesicles are a novel chronic wound therapeutic
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2019 · $1,996,911
Sep 30, 2019 – Apr 30, 2021
Solicitation PAR18-183 (2018) · Topic NIA
A Novel Human Primary Meibomian Gland Cell Platform for Dry Eye Therapeutics
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2018 · $216,626
Sep 30, 2018 – Aug 31, 2019
Solicitation PAR16-375 (2016) · Topic NIA
Selective Tuning of Stem Cell Extracellular Vesicles as a Novel Therapy for Age-related Tendinopathy
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2018 · $221,826
Mar 15, 2018 – Feb 28, 2019
Solicitation PAR16-375 (2016) · Topic NIA
Tuned stem cell extracellular vesicles as a novel chronic wound therapeutic
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2017 · $223,180
Sep 15, 2017 – Aug 31, 2018
Solicitation PAR16-375 (2016) · Topic NIA
Development and validation of a human brown adipocyte system
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2016 · $1,499,548
Sep 19, 2016 – Nov 30, 2018
Solicitation PA15-269 (2015) · Topic 200
A novel class of anti-acne therapeutics
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2016 · $224,999
Sep 1, 2016 – Aug 31, 2017
Solicitation PA15-269 (2016) · Topic NIAMS
Development and validation of a human brown adipocyte system
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2015 · $224,320
Mar 1, 2015 – Feb 29, 2016
Solicitation PA14-071 (2015) · Topic 200
IGF OT IGF HIGH CONTENT SCREENING FOR HUMAN PRIMARY PANCREATIC CELL TYPE SPECIFIC TOXICANTS
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2015 · $224,901
Solicitation year 2015 · Topic NIDA
Selective Fyn kinase inhibitors for treatment of metabolic disease
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2014 · $1,498,715
May 1, 2014 – Apr 30, 2016
Solicitation PA13-234 (2014) · Topic 200
Development of a drug discovery platform for human islets
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2014 · $1,754,814
Apr 10, 2014 – Mar 31, 2016
Solicitation PA13-088 (2014) · Topic 200
Identification of potent and selective GLI1 inhibitors
STTR Phase I · Department of Health and Human Services (National Institutes of Health) · 2013 · $289,934
Solicitation PA12-089 (2013) · Topic NCI · Research partner: NORTH CAROLINA CENTRAL UNIVERSITY
Development of a Drug Discovery Platform for Human Islets
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2012 · $462,386
Solicitation PA11-096 (2012) · Topic NIDDK · Research partner: Stub
Development of a human skeletal muscle cell-based high throughput screen for musc
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2011 · $251,144
Solicitation PA10-050 (2011) · Topic NIAMS · Research partner: Stub
Selective Fyn kinase inhibitors for treatment of metabolic disease
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2011 · $350,681
Solicitation PA10-050 (2011) · Topic NIDDK · Research partner: Stub
Alternative human cell-based models of fatty liver disease
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2010 · $227,197
Solicitation PHS2010-2 (2010) · Topic NIDDK
Diabetes Therapies from Adipose Derived Stem Cells
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2010 · $363,202
Solicitation PHS2010-2 (2010) · Topic NIDDK
Commercialization of Human Mammary Basal / Luminal Cell System for Research
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2010 · $1,285,560
Solicitation PHS2010-2 (2010) · Topic NCI
Commercialization of Human Mesothelial Cells for Research
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2009 · $1,888,390
Solicitation PHS2009-2 (2009)
Botannical Extract Library Screeninig with Human ADAS Cells
STTR Phase I · Department of Health and Human Services (National Institutes of Health) · 2008 · $228,954
Solicitation PHS2007-2 (2008)
Commercialization of Human Mammary Basal / Luminal Cell System for Research
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2008 · $206,649
Solicitation PHS2007-2 (2008)
Commercialization of a Human Myocyte and Adipocyte Co-Culture System
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2008 · $1,383,210
Solicitation PHS2007-2 (2008)
Commercialization of a Human Myocyte and Adipocyte Co-Culture System
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2007 · $184,782
Solicitation year 2007
Commercialization of Human Omental Mesothelial Cells for Research
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2007 · $86,730
Solicitation year 2007
Commercialization of Human Visceral Adipocytes
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2005 · $961,578
Solicitation PHS2005-2 (2005)
Commercialization of Human Visceral Adipocytes
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2003 · $100,000
Source: SBIR.gov award data file (opens in a new tab) · as of Nov 12, 2026 · file published Nov 1, 2026
FedRAMP offerings
No FedRAMP Marketplace listing
Source: FedRAMP Marketplace (opens in a new tab) · sync date not recorded
Exclusions & screening
SAM.gov exclusions
Not yet checked against SAM.gov exclusions.
Agencies generally may not award to excluded parties, and primes may not subcontract with them above the threshold in FAR 52.209-6 (except COTS items) without a compelling reason reported to the contracting officer (FAR 9.405, 9.405-2). Some exclusion types apply only to specific programs: read the record on SAM.gov.
Source: SAM.gov Exclusions (opens in a new tab) · sync date not recorded
Consolidated Screening List
No confirmed match on the Consolidated Screening List (screened Nov 13, 2026).
The list combines Commerce, State and Treasury export-control and sanctions lists. A “no match” result is a name-and-address screen, not an export-compliance determination.
Source: ITA Consolidated Screening List (opens in a new tab) · as of Nov 13, 2026
GSA CALC+ rate benchmark
No GSA CALC+ rates on record
Source: GSA CALC+ awarded ceiling rates (opens in a new tab) · sync date not recorded
NAICS, PSC & socio-economic status
NAICS codes
- 325414Biological Product (except Diagnostic) ManufacturingPrimarySmall business under this code’s size standard
- 541380Testing Laboratories and Services
- 541714Research and Development in Biotechnology (except Nanobiotechnology)Small business under this code’s size standard
- 541715Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- 621511Medical Laboratories
SAM.gov reports this entity as small under 2 of 5 NAICS codes. Size is determined per code (SBA size standards).
Product & service codes (PSC)
- AN12HEALTH R&D SERVICES; HEALTH CARE SERVICES; APPLIED RESEARCH
- B504SPECIAL STUDIES/ANALYSIS- CHEMICAL/BIOLOGICAL
PSC names from the Acquisition.gov PSC Manual (opens in a new tab) (April 2025 edition), checked Nov 12, 2026.
Teaming preferences
This company has not published teaming preferences.
Business development contact
No BD contact published
Corporate hierarchy
No parent entity reported in SAM.gov.
SBA counts affiliates when it determines whether a business is small (13 CFR 121.103), so a parent’s size can matter for set-aside work.
Data sources & provenance
SAM.gov
Registration, CAGE, NAICS, socio-economic status, corporate hierarchy and exclusions. Last synced Nov 9, 2026.
USAspending.gov
Prime award history and obligations (FPDS), synced nightly.
The contractor
Nothing yet: this profile has not been claimed by the company.
TeamingIndex verification
Credentials marked Verified were checked by a TeamingIndex reviewer; everything else is self-attested.
Corrections
Corrections to SAM.gov data must be made in SAM.gov; TeamingIndex picks them up on the next nightly sync. Go to SAM.gov (opens in a new tab)
Machine-readable: capability.md schema.org JSON-LD embedded in this page.
Zero CUI: TeamingIndex stores verification metadata only, never System Security Plans, POA&Ms or DD Form 254s.
Teaming
Ready to team with ZEN-BIO, INC.?
Send an introduction and propose a mutual NDA. Their team is notified right away, and you can share the capability statement with your capture team.